Viking Therapeutics (VKTX) Operating Expenses (2014 - 2026)

Viking Therapeutics has disclosed Operating Expenses across 13 years of filings, most recently posting $132.6 million for Q2 2026.

• In Q2 2026, Operating Expenses rose 77.81% year-over-year to $132.6 million; the TTM figure through Jun 2026 stood at $560.0 million (up 163.12% YoY), while the FY2025 annual figure was $393.3 million, up 160.63% from the prior year.
• Operating Expenses came in at $132.6 million for Q2 2026 at Viking Therapeutics, down from $164.1 million in the prior quarter.
• In the past five years, Operating Expenses ranged from a high of $164.7 million in Q4 2025 to a low of $16.2 million in Q3 2022.
• Average Operating Expenses over 5 years is $56.2 million, with a median of $34.1 million recorded in 2024.
• Year-over-year, Operating Expenses rose 13.45% in 2022 and surged 256.28% in 2025.
• Over 5 years, Operating Expenses stood at $20.3 million in 2022, then surged by 44.38% to $29.3 million in 2023, then jumped by 57.89% to $46.2 million in 2024, then surged by 256.28% to $164.7 million in 2025, then decreased by 19.51% to $132.6 million in 2026.
• Per Business Quant data, the three most recent Operating Expenses figures were $132.6 million in Q2 2026, $164.1 million in Q1 2026, and $164.7 million in Q4 2025.